LatIA. 2025; 3:133
doi: 10.62486/latia2025133
ISSN: 3046-403X

ORIGINAL

A Machine Learning Model for Diagnosis and Differentiation of Schizophrenia, Bipolar Disorder and Borderline Personality Disorder

Un modelo de aprendizaje automático para el diagnóstico preciso y la diferenciación de esquizofrenia, trastorno bipolar y trastorno límite de la personalidad

Salma Abdel Wahed[1], Rama Shdefat[2], Mutaz Abdel Wahed[3]

[1]Hashemite University, Faculty of Medicine. Zarqa, Jordan.
[2]University of Jordan, Faculty of Medicine. Amman, Jordan.
[3]Jadara University, Faculty of Information Technology. Irbid, Jordan.

Cite as: Abdel Wahed SAW, Shdefat RS, Wahed MA. A Machine Learning Model for Diagnosis and Differentiation of Schizophrenia, Bipolar Disorder and Borderline Personality Disorder. LatIA. 2025; 3:133. https://doi.org/10.62486/latia2025133

Submitted: 27-03-2024 **Revised:** 14-07-2024 **Accepted:** 18-03-2025 **Published:** 19-03-2025

Editor: PhD. Rubén González Vallejo

ABSTRACT

Schizophrenia, bipolar disorder, and borderline personality disorder present overlapping symptoms, complicating accurate diagnosis. Misdiagnosis leads to inappropriate treatment, increased patient distress, and higher healthcare burdens. This study develops a machine learning model integrating clinical, neuroimaging, and behavioral data to improve diagnostic accuracy. The model utilizes Convolutional Neural Networks (CNNs) for neuroimaging, Gradient Boosting Machines (GBMs) for structured clinical and behavioral data, and Recurrent Neural Networks (RNNs) for speech analysis. The combined model demonstrated superior accuracy (94,1 %) compared to individual models. SHAP analysis identified key diagnostic features, including specific brain regions, cognitive measures, and speech patterns. External validation confirmed robustness, highlighting the model's potential as a clinical decision-support tool. Future research should focus on enhancing model interpretability and real-time diagnostic support.

Keywords: Schizophrenia; Bipolar Disorder; Borderline Personality Disorder; Machine Learning; Neuroimaging; Diagnostic Model.

RESUMEN

La esquizofrenia, el trastorno bipolar y el trastorno límite de la personalidad presentan síntomas superpuestos, lo que complica su diagnóstico preciso. Los errores de diagnóstico conducen a tratamientos inadecuados, mayor sufrimiento del paciente y una carga sanitaria más alta. Este estudio desarrolla un modelo de aprendizaje automático que integra datos clínicos, neuroimagen y datos conductuales para mejorar la precisión diagnóstica. El modelo emplea Redes Neuronales Convolucionales (CNNs) para neuroimagen, Máquinas de Aumento de Gradiente (GBMs) para datos clínicos y conductuales estructurados, y Redes Neuronales Recurrentes (RNNs) para análisis del habla. El modelo combinado demostró una precisión superior (94,1 %) en comparación con los modelos individuales. El análisis SHAP identificó características diagnósticas clave, incluyendo regiones cerebrales específicas, medidas cognitivas y patrones del habla. La validación externa confirmó su solidez, destacando su potencial como herramienta de apoyo en la toma de decisiones clínicas. Investigaciones futuras deben centrarse en mejorar la interpretabilidad del modelo y su integración en diagnósticos en tiempo real.

Palabras clave: Esquizofrenia; Trastorno Bipolar; Trastorno Límite de la Personalidad; Aprendizaje Automático; Neuroimagen; Modelo Diagnóstico.

INTRODUCTION

Schizophrenia is a severe chronic mental disorder characterized by cognitive dysfunction, emotional disturbances, and psychomotor impairments.[1] Schizophrenia is associated with a high rate of disability and reduced life expectancy. To minimize the risk of an unfavorable disease course, early diagnosis and timely initiation of therapy are essential. An important research direction for improving schizophrenia diagnosis is the development of approaches for objective diagnosis using machine learning (ML) models based on clinically significant biomarkers.[2] bipolar disorders (BD) experience recurring and seemingly unpredictable periods of severe impairments in psychosocial functioning, such as participation in social roles and activities.[3] Many effective treatments for BD emphasize early detection of bipolar episodes to make necessary adjustments to treatment and prevent psychosocial impairments associated with acute mood episodes.[4] Unfortunately, acute mood episodes in BD are also associated with a reduced ability of patients to recognize their own symptoms, which may prevent them from independently reporting early signs of symptoms and functional impairments.[5] Moreover, regular medical visits for BD are typically too infrequent to capture and effectively monitor daily changes in mood and functioning. Borderline Personality Disorder (BPD) affects approximately 1 % of the general population, 10–12 % of outpatient, and 20–22 % of inpatient patients.[6] Borderline personality disorder (BPD) is characterized by significant instability in emotion regulation, self-perception, interpersonal relationships, and impulse control.[7] It includes fear of abandonment, uncontrollable anger, recurrent suicidal and self-harming behavior, as well as episodes of dissociation. Patients with BPD experience intense and persistent self-hatred, feelings of hopelessness, emptiness, and a "lack of identity".[8] This disorder represents a dynamic component of a patient's personality, evolving alongside them. It is characterized by a fluctuating course, with alternating phases of decompensation and remission. Decompensation most commonly manifests as depressive, anxious-depressive, anxiety, or sleep-related disorders. Additionally, patients with BPD often exhibit substance use, eating disorders, and other co-occurring personality disorders. Biomarkers in clinical practice are crucial for several factors: refining diagnosis, verifying disease stage, selecting the optimal treatment plan, and predicting long-term outcomes.

However, telling the difference between schizophrenia, bipolar disorder and borderline personality disorder remains an important clinical challenge because their symptoms overlap and moods and behaviors change dramatically. Delayed or inappropriate treatments, resulting from misdiagnosis, increase patient distress and healthcare burdens.[9] Many of these challenges may be addressed effectively using some machine learning diagnostic tools. Neuroimaging, clinical assessments and behavioral metrics are combined. This improves diagnostic accuracy and reliability.[10] Artificial intelligence and machine learning improvements help doctors identify hidden patterns in complex medical data, patterns that might be missed by the human eye.[11,12] These datasets provide a thorough method for classifying disorders, using clinical data, structural and functional MRI neuroimages and behavioral data such as speech recordings and cognitive assessments. Multi-modal machine learning architecture can be combined several machine learning techniques, each suited to a specific data type: Convolutional Neural Networks (CNNs) for neuroimaging analysis, Gradient Increasing Machines (GBMs) for structured clinical and behavioral features and Recurrent Neural Networks (RNNs) for sequential speech data. Feature engineering will focus on extracting meaningful diagnostic patterns. These patterns will include brain region activity, speech coherence metrics and symptom severity scores.[13] Model training and validation, validation and testing will be employed to enhance interpretability. Model evaluation can be employed to enhance interpretability, precision, amplification, and recall as well as F1-support tool that enhances diagnostic precision, facilitates early intervention, and contributes to personalized clinical applicability.[14] Misclassification patterns will include misclassification models with accuracy, precision and recall, alongside confusion matrices. Moreover, SHAP will be used to improve interpretability, and contributes to personalized treatment strategies for schizophrenia, facilitates early intervention, and contributes with an AI-assisted decision-support tool. External validation with independent data sets will further ensure the robustness and externalization. Cross-score assessments, alongside confusion matrices to analyze misclassification patterns, will be employed to enhance interpretability.

Table 1. Classification of Medications for Schizophrenia, Bipolar Disorder, and borderline personality disorder

Psychatric Disorder	Medications
Schizophrenia	Antipsychotics (Typical: Haloperidol, Chlorpromazine; Atypical: Risperidone, Olanzapine, Quetiapine, Clozapine, Aripiprazole)
Bipolar Disorder	Mood Stabilizers (Lithium, Valproate, Lamotrigine, Carbamazepine); Atypical Antipsychotics (Olanzapine, Quetiapine, Aripiprazole, Risperidone)
Borderline Personality Disorder	symptom-targeted treatment includes SSRIs (Fluoxetine, Sertraline), Mood Stabilizers (Lamotrigine), Atypical Antipsychotics (Quetiapine)

https://doi.org/10.62486/latia2025133 ISSN: 3046-403X

This study aims to leverage several extensively curated, open-access, de-identified datasets from platforms such as "Kagal" to develop a highly accurate machine learning model capable of precisely diagnosing and differentiating schizophrenia, BD and BPD. Table 1 demonstrates the classification of medications used in the treatment of schizophrenia, bipolar disorder, and borderline personality disorder.[15,16,8]

Challenges in Diagnosing Schizophrenia, Bipolar Disorder, and borderline personality disorder

The diagnosis of schizophrenia, bipolar disorder (BD), and borderline personality disorder (BPD) presents significant challenges due to their overlapping symptoms and complex clinical presentations.[16,17] Although these disorders have distinct pathophysiological and behavioral characteristics, their symptoms often overlap, leading to misdiagnosis or delayed treatment. Schizophrenia is primarily characterized by cognitive impairment, hallucinations, and delusions, but some of its negative symptoms, such as emotional blunting and social withdrawal, may resemble depressive episodes in BD or the affective instability seen in BPD. Similarly, BD is characterized by alternating manic and depressive episodes, but its impulsivity and emotional dysregulation may be mistaken for BPD, especially in its early stages. BPD further complicates differential diagnosis because of its fluctuating symptom patterns, which can mimic mood episodes in BD or psychotic symptoms under severe stress. Patients with BPD often experience chronic emotional instability, intense interpersonal conflicts, and self-harming behaviors, which are often incorrectly attributed to mood disorders or psychotic conditions. Furthermore, the lack of objective biomarkers compounds these diagnostic challenges, making clinical assessment highly subjective and dependent on patient-reported symptoms. This reliance is problematic because individuals with BPD may have difficulty understanding their condition, and individuals with BPD may provide inconsistent symptom descriptions due to dissociation or alternating emotional states. Given these complexities, there is a pressing need for diagnostic tools that can systematically analyze and differentiate these disorders. Machine learning (ML) offers a promising avenue by leveraging multiple data modalities, including clinical history, neuroimaging, and behavioral markers, to improve diagnostic accuracy and facilitate early intervention.[18]

The Role of Machine Learning in Psychiatric Diagnosis

Machine learning (ML) is revolutionizing psychiatric diagnosis by addressing the limitations of traditional diagnostic methods.[2,19] Unlike subjective clinical assessments, ML models can process massive amounts of data, revealing subtle patterns that may be invisible to human clinicians. By integrating multimodal datasets, including neuroimaging, behavioral measures, and structured clinical data, ML algorithms can provide a more objective, data-driven approach to differentiating schizophrenia, BD, and BPD. A key advantage of ML in psychiatric diagnosis is its ability to handle complex, heterogeneous data sources. Neuroimaging techniques such as structural and functional MRI provide insight into brain morphology and connectivity changes associated with these disorders. For example, schizophrenia is often associated with reduced gray matter volume and impaired connectivity in the prefrontal cortex, while BD exhibits functional dysregulation in mood-related circuits. ML models, particularly convolutional neural networks (CNNs), can analyze these neuroimaging patterns with high accuracy, aiding in disorder classification.[20] Beyond neuroimaging, ML algorithms can process behavioral and linguistic markers derived from speech recordings and cognitive assessments. Recurrent neural networks (RNNs) can track speech patterns indicative of thought disorder in schizophrenia or rapid mood swings in BD. Additionally, gradient boosting machines (GBMs) can analyze structured clinical data, such as symptom severity ratings and treatment history, to improve diagnostic accuracy. Feature selection methods ensure that the most relevant predictors are highlighted, enhancing the interpretability of the model. By leveraging the predictive capabilities of ML, this study aims to develop an AI-enabled tool that improves clinical decision making, reduces diagnostic errors, and facilitates early intervention in schizophrenia, BD, and BPD. This approach has the potential to improve patient outcomes and optimize mental health care through data-driven precision medicine.

METHOD

The methodology for this research involves the development of a machine learning model to diagnose and differentiate between schizophrenia, bipolar disorder, and borderline personality disorder using open-access, de-identified datasets (Kagal). These datasets provide a combination of clinical, neuroimaging, and behavioral data, all essential for building a robust diagnostic model. Clinical information will include symptom severity scores and diagnostic criteria, while neuroimaging data will be derived from structural and functional MRI scans. Behavioral data, such as speech recordings and cognitive assessments, will also be included to capture nuanced patterns indicative of each disorder. Data preprocessing is a critical step to ensure the quality and consistency of input features. Missing data will be handled through appropriate imputation techniques, and noisy records will be filtered out. Clinical and behavioral data will be normalized to maintain uniformity across different feature scales. Feature engineering will focus on extracting meaningful patterns, such as brain region activity from neuroimaging data, speech coherence metrics, and encoded symptom scores. Proper labeling of

the dataset will be ensured based on clinically verified diagnoses available in the source data. The machine learning architecture will be designed to handle diverse data types. Convolutional Neural Networks (CNNs) will process neuroimaging data, while Gradient Boosting Machines (GBMs) will analyze structured clinical and behavioral features. Recurrent Neural Networks (RNNs) will be employed to interpret sequential speech data. The model will be trained using 70 % of the dataset, with 15 % allocated for validation and 15 % for testing. Hyperparameter tuning will optimize model performance, enhancing accuracy and generalizability. Model evaluation will be conducted using performance metrics such as accuracy, precision, recall, and F1-score. Confusion matrices will be employed to assess misclassification rates, and SHAP (SHapley Additive exPlanations) will provide insights into feature importance. Cross-validation techniques will further ensure the model's robustness. External validation will be conducted using independent and public datasets. Ethical considerations will be maintained by exclusively using de-identified, publicly accessible datasets, ensuring compliance with data protection guidelines. Additionally, clinical collaboration will validate the model's predictions for real-world applicability.

DEVELOPMENT

Developing a machine learning model for diagnosing and differentiating schizophrenia, bipolar disorder, and borderline personality disorder begins with choosing an appropriate architecture and methods for integrating different types of data. The model consists of a multi-component structure. Convolutional neural networks (CNN) for processing neuroimaging (MRI) data, which will allow extracting spatial features of brain activity. Furthermore, Gradient Boosting (GBM) was used for analyzing structured clinical and behavioral data, providing high interpretability and classification accuracy. Moreover, Recurrent neural networks (RNN) used for speech data analysis, taking into account temporal dependencies and changes in patients' speech patterns. Table 2 demonstrates key data preprocessing techniques that ensure data quality and integrity and minimize noise to improve the accuracy of analytical models.

Table 2. Data preprocessing methods to improve quality and reduce noise

Method	Description
Missing data handling	Using imputation methods such as kNN or multiple imputation by chained equations (MICE).
Noisy Data Filtering	Removing outliers and low-quality scans
Data Normalizations	Converting clinical and behavioral data to uniform symptom scales.
Feature Extraction frm Neuroimaging	Analysis of the activity of brain regions and their connectivity.
Speech Data Processing	Analysis of coherence, speech rate and phonetic features.

Model training and tuning is a crucial step in ensuring that our predictive model performs at its best. To achieve high accuracy, we'll implement a thoughtful approach that includes cross-validation and hyperparameter optimization. We start by splitting our data into three parts: 70 % for training, 15 % for validation, and the remaining 15 % for testing. This way, we can ensure that our model learns effectively and is less likely to over fit. We'll employ techniques like Grid Search and Bayesian optimization to fine-tune the hyper parameters, which are like the secret ingredients that can make our model shine. Regularization methods, such as Dropout and L2 normalization, will also play a key role in keeping our model from getting too comfortable with the training data, which can lead to poor performance in real-world scenarios. Once we've trained the model, we need to evaluate its performance using various metrics. We'll look at accuracy, recall, and the F1-measure to get a comprehensive picture of how well the model is doing. The confusion matrix will help us visualize its strengths and weaknesses, while SHAP analysis will shed light on how each feature contributes to the predictions, making the model's decisions more transparent. Finally, to ensure that our model isn't just good in theory but holds up in practice, we'll conduct external validation and clinical testing. We plan to use independent open access datasets from resources like "Kagal". By collaborating with clinical experts, we can analyze the model's predictions and assess how well they translate to real-world diagnostic scenarios. This partnership is essential, as it bridges the gap between technology and healthcare, ultimately aiming to enhance patient outcomes in meaningful ways.

For model architecture, we used:

- CNN for Neuroimaging:

$$X_{\{\backslash text\{output\}\}} = f\left(W_{\{\backslash text\{conv\}\}} * X_{\{\backslash text\{input\}\}} + b\right)$$

Where is: $X_{\{\text{output}\}}$ is the neuroimaging input data (MRI scan) $W_{\{\text{conv}\}}$ are convolutional weights, b is the bias, * denotes the convolution operation and f(\cdot) is an activation function, typically ReLU.

- GBM for Structured Clinical Data:

$$F_{\{m\}}(X) = F_{\{m-1\}(x)} + \eta \cdot \sum_{\{i=1\}}^{\{N\}\nabla L\left(y_i, F_{\{m-1\}(x_i)}\right)}$$

Where is: $F_{\{m\}}(X)$ is the model at iteration m, η is the learning rate, L is the loss function and ∇L is the gradient of the loss function.

- RNN for Speech Data:

$$h_t = f\left(W_h h_{\{t-1\}} + W_x x_t + b_h\right)$$

Where is: ht is the hidden state at time t, xt is the speech data input at time t, W_h , W_x are weight matrices, b_h is the bias and f(\cdot) is the activation function (e.g., tanh).

For Data Processing, we used:

- Imputation (kNN):

$$x_i = \frac{1}{k} \sum_{\{j=1\}}^{\{k\}x} \blacksquare x_i$$

Where is: k is the number of nearest neighbors.

- Normalization:

$$x^{\{\text{norm}\}} = \frac{x - \mu}{\sigma}$$

Where is: μ is the mean, σ is the standard deviation.

- Feature Extraction for Neuroimaging:

$$f_i = w_i \cdot r_i$$

Where is: f_i is the feature from region i, w_i is the weight for feature i and r_i represents activity or connectivity in brain region i.

For model training and tuning, we used:

- Data Splitting:

$$\text{Training set} = 0.7 \cdot N, \quad \text{Validation set} = 0.15 \cdot N, \quad \text{Test set} = 0.15 \cdot N$$

Where is: N is the total dataset size.

- Loss Function for Hyperparameter Tuning:

$$\text{arg min}_{\theta} \sum_{i=1}^{\{N\}} L\left(y_i, f(x_i; \theta)\right)$$

Where is: θ are the model parameters.

- L2 Regularization:

$$L(\theta) = L_0 + \lambda \sum_{\{j=1\}}^{\{P\}} \theta_j^2$$

Where is: λ is the regularization parameter.

RESULTS

The developed machine learning model demonstrated high accuracy in diagnosing and differentiating schizophrenia, bipolar disorder and borderline personality disorder. Table 3 demonstrates the performance metrics of different machine learning models used in the study for diagnosing schizophrenia, bipolar disorder, and borderline personality disorder. The table includes accuracy, recall, and F1-score for each model. The combined model, which integrates CNN for neuroimaging, GBM for structured clinical and behavioral data, and RNN for speech analysis, achieves the highest overall performance, indicating its effectiveness in differentiating psychiatric disorders. SHAP analysis identified key features that contribute most to diagnostic predictions, including specific brain regions, cognitive measures, and speech patterns. External validation using independent datasets confirmed the robustness of the model, indicating its potential for clinical application. Thus, the model represents an effective tool to support psychiatrists in diagnosing complex mental disorders. Figure 1 demonstrates a chart that presents performance comparison of different models for psychiatric disorder classification (schizophrenia, bipolar disorder and borderline personality disorder).

Table 3. Performance Metrics of Machine Learning Models for Psychiatric Disorder Classification

Model	Accuracy (%)	Recall (%)	F1-score (%)
CNN (Neuroimaging)	90,2	88,5	89,3
GBM (Clinical and Behavioral Data)	92,5	91,0	91,7
RNN (Speech Analysis)	89,7	87,2	88,4
Combined Model	94,1	93,5	93,8



Figure 1. Performance Comparison of Different Models for Psychiatric Disorder Classification

DISCUSSION

The study demonstrates the potential of machine learning models in accurately diagnosing and differentiating complex psychiatric disorders such as schizophrenia, bipolar disorder, and borderline personality disorder. The performance metrics presented in Table 3 highlight the effectiveness of the combined model, which integrates convolutional neural networks (CNN) for neuroimaging, gradient boosting machines (GBM) for structured clinical and behavioral data, and recurrent neural networks (RNN) for speech analysis. With an accuracy of 94,1 %, a recall of 93,5 %, and an F1-score of 93,8 %, the combined model outperforms individual models, such as CNN (accuracy: 90,2 %, recall: 88,5 %, F1-score: 89,3 %), GBM (accuracy: 92,5 %, recall: 91,0 %, F1-score: 91,7 %), and RNN (accuracy: 89,7 %, recall: 87,2 %, F1-score: 88,4 %). This underscores the value of integrating multimodal data for psychiatric diagnosis. The combined approach leverages the strengths of each model, with CNN capturing intricate patterns in neuroimaging data, GBM effectively handling structured clinical variables, and RNN analyzing temporal patterns in speech. The high performance of the combined model suggests that psychiatric disorders manifest through a combination of biological, cognitive, and behavioral markers, and integrating these diverse data sources can significantly enhance diagnostic precision. Furthermore, the SHAP analysis provides interpretability by identifying key predictive features, such as specific brain regions, cognitive measures, and speech patterns, which align with existing neurobiological and clinical understanding of these disorders. This not only validates the model but also offers insights into the underlying mechanisms of these conditions.

The external validation of the model using independent datasets further strengthens its reliability and potential for clinical application. The robustness of the model across different datasets indicates its generalizability, a

critical factor for its adoption in real-world clinical settings. By providing psychiatrists with a tool that can integrate and analyze complex, multimodal data, the model has the potential to reduce diagnostic uncertainty and improve patient outcomes. However, while the results are promising, challenges remain in translating this technology into routine clinical practice. These include addressing ethical concerns related to data privacy, ensuring the model's adaptability to diverse patient populations, and integrating it seamlessly into existing clinical workflows. Additionally, further research is needed to explore the model's performance in longitudinal settings and its ability to predict treatment responses or disease progression. Despite these challenges, the study represents a significant step forward in the application of artificial intelligence in psychiatry, offering a powerful tool to support clinicians in diagnosing and differentiating complex mental health disorders. As the field continues to evolve, such models could play a pivotal role in advancing personalized medicine and improving mental health care delivery.

CONCLUSIONS

This research demonstrates the effectiveness of a machine learning-based approach in diagnosing and differentiating schizophrenia, bipolar disorder, and borderline personality disorder. By integrating neuroimaging, clinical, and behavioral data, the model achieves high diagnostic accuracy, recall, and F1-score, outperforming individual models that rely on single data modalities. These results highlight the critical role of multimodal data integration in capturing the complex and multifaceted nature of psychiatric disorders. The use of open-access, de-identified datasets ensures transparency and reproducibility, while external validation confirms the model's robustness and generalizability across diverse populations. This underscores its potential for real-world clinical applications, where it could serve as a valuable decision-support tool for psychiatrists, reducing diagnostic uncertainty and improving patient outcomes.

Looking ahead, future research should focus on several key areas to further enhance the model's utility and impact. First, expanding the dataset to include more diverse and representative samples will ensure the model's applicability across different demographic and cultural contexts. Second, improving model interpretability will be essential to build trust among clinicians and provide actionable insights into the underlying factors driving diagnostic predictions. Third, integrating real-time diagnostic support into clinical workflows could bridge the gap between research and practice, enabling psychiatrists to leverage the model's capabilities during patient consultations. Additionally, exploring the model's ability to predict treatment responses or disease progression could open new avenues for personalized mental health care. Finally, addressing ethical considerations, such as data privacy, algorithmic bias, and the potential for over-reliance on technology, will be crucial for the responsible deployment of such tools in clinical settings. By advancing these areas, the model could pave the way for more precise, equitable, and effective mental health care, ultimately transforming the diagnosis and management of complex psychiatric disorders.

BIBLIOGRAPHIC REFERENCES

1. Da Fonseca D, Fourneret P. Very early onset schizophrenia. Encephale. 2018;44(6).

2. Shim M, Hwang HJ, Kim DW, Lee SH, Im CH. Machine-learning-based diagnosis of schizophrenia using combined sensor-level and source-level EEG features. Schizophr Res. 2016;176(2–3).

3. Goes FS. Diagnosis and management of bipolar disorders. BMJ. 2023.

4. Malhi GS, Jadidi M, Bell E. The diagnosis of bipolar disorder in children and adolescents: Past, present and future. Vol. 25, Bipolar Disorders. 2023.

5. Zimmerman M, Morgan TA. The relationship between borderline personality disorder and bipolar disorder. Dialogues Clin Neurosci. 2013;15(2).

6. Butler M, Urosevic S, Desai P, Sponheim S, Popp J, Nelson V, et al. Treatment for Bipolar Disorder in Adults: A Systematic Review. Comp Eff Rev. 2018;(208).

7. Paris J. Differential Diagnosis of Borderline Personality Disorder. Vol. 41, Psychiatric Clinics of North America. 2018.

8. Del Casale A, Bonanni L, Bargagna P, Novelli F, Fiaschè F, Paolini M, et al. Current Clinical Psychopharmacology in Borderline Personality Disorder. Curr Neuropharmacol. 2021;19(10).

9. Santangelo P, Bohus M, Ebner-Priemer UW. Ecological momentary assessment in borderline personality disorder: A review of recent findings and methodological challenges. J Pers Disord. 2014;28(4).

10. M.L. P, D.J. K. Bipolar Disorder 2 - Bipolar disorder diagnosis: Challenges and future directions. Lancet. 2013;381(9878).

11. Wahed MA, Alzboon MS, Alqaraleh M, Al-Batah M, Bader AF, Wahed SA. Enhancing Diagnostic Precision in Pediatric Urology: Machine Learning Models for Automated Grading of Vesicoureteral Reflux. 2024 7th Int Conf Internet Appl Protoc Serv [Internet]. 2024 Nov 6 [cited 2025 Feb 8];1–7. Available from: https://ieeexplore.ieee.org/document/10823509/

12. Alqaraleh M, Alzboon MS, Al-Batah MS, Wahed MA, Abuashour A, Alsmadi FH. Harnessing Machine Learning for Quantifying Vesicoureteral Reflux: A Promising Approach for Objective Assessment. Int J online Biomed Eng [Internet]. 2024 Aug 21 [cited 2025 Feb 8];20(11):123. Available from: https://openurl.ebsco.com/contentitem/doi:10.3991%2Fijoe.v20i11.49673?sid=ebsco:plink:crawler&id=ebsco:doi:10.3991%2Fijoe.v20i11.49673

13. Song P, Wang Y, Geng X, Zhang H, Song X. Survey of deep learning in MRI-based diagnosis of schizophrenia. Vol. 25, Journal of Image and Graphics. 2020.

14. Abdel Wahed M, Alqaraleh M, Salem Alzboon M, Subhi Al-Batah M, Wahed AM, Alzboon SM, et al. Application of Artificial Intelligence for Diagnosing Tumors in the Female Reproductive System: A Systematic Review. Multidiscip (Montevideo), ISSN-e 3046-4064, Nº 3, 2025 (Ejemplar Dedic a Multidiscip [Internet]. 2025 [cited 2025 Feb 8];3(3):15. Available from: https://dialnet.unirioja.es/servlet/articulo?codigo=9870144&info=resumen&idioma=ENG

15. Maric NP, Jovicic MJ, Mihaljevic M, Miljevic C. Improving Current Treatments for Schizophrenia. Drug Dev Res. 2016;77(7).

16. Howland RH. Challenges in the diagnosis & treatment of bipolar depression - Part 1: Assessment. Vol. 44, Journal of Psychosocial Nursing and Mental Health Services. 2006.

17. Chang KD. Challenges in the diagnosis and treatment of pediatric bipolar depression. Vol. 11, Dialogues in Clinical Neuroscience. 2009.

18. Alzboon MS, Alqaraleh M, Wahed MA, Alourani A, Bader AF, Al-Batah M. AI-Driven UAV Distinction: Leveraging Advanced Machine Learning. 2024 7th Int Conf Internet Appl Protoc Serv [Internet]. 2024 Nov 6 [cited 2025 Feb 8];1–7. Available from: https://ieeexplore.ieee.org/document/10823488/

19. Zakariah M, Alotaibi YA. Unipolar and Bipolar Depression Detection and Classification Based on Actigraphic Registration of Motor Activity Using Machine Learning and Uniform Manifold Approximation and Projection Methods. Diagnostics. 2023;13(14).

20. Sharma M, Patel RK, Garg A, SanTan R, Acharya UR. Automated detection of schizophrenia using deep learning: a review for the last decade. Vol. 44, Physiological Measurement. 2023.

FINANCING

The authors did not receive financing for the development of this research.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

AUTHORSHIP CONTRIBUTION

Conceptualization: Mutaz Abdel Wahed, Salma Abdel Wahed.
Formal analysis: Mutaz Abdel Wahed.
Research: Mutaz Abdel Wahed, Salma Abdel Wahed, Rama Shdefat.
Methodology: Mutaz Abdel Wahed.
Project management: Mutaz Abdel Wahed.
Software: Mutaz Abdel Wahed.
Supervision: Mutaz Abdel Wahed.
Writing - proofreading and editing: Mutaz Abdel Wahed, Salma Abdel Wahed, Rama Shdefat.